The Food and Drug Administration (FDA) has approved Vykat™ XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome ...
Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is ...
Griffith-Atkins, a therapist and the parent of a child with Prader-Willi syndrome, invites fellow caregivers to acknowledge ...
Becoming the first treatment for rare genetic disorder Prader-Willi syndrome, breakthrough therapy drug DCCR (diazoxide choline) gained U.S. FDA approval as Vykat XR the evening before its March 27 ...
Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...
The FDA has approved the first therapy to address hyperphagia for children and adults aged 4 years and older with ...
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating ...
Vykat XR is specifically indicated to address hyperphagia, or the abnormally strong sensation of hunger, which often leads to ...
The U.S. Food and Drug Administration approved Soleno Therapeutics' drug to treat a rare genetic disorder on Wednesday, ...
(Reuters) -The U.S. Food and Drug Administration on Wednesday approved Soleno Therapeutics' drug to treat a rare genetic ...
The 17-year-old has grown up in the spotlight thanks to her famous parents' many TV projects over the years, with her birth ...
Ionis and Ultragenyx are competing to develop oligonucleotide treatments for Angelman syndrome, but will Neuren’s peptide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback